Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, February 2001, p. 439-446, Vol. 45, No. 2
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.2.439-446.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
High-Affinity Binding of Silybin Derivatives to the
Nucleotide-Binding Domain of a Leishmania tropica
P-Glycoprotein-Like Transporter and Chemosensitization of a
Multidrug-Resistant Parasite to Daunomycin
José M.
Pérez-Victoria,1
F. Javier
Pérez-Victoria,1
Gwenaëlle
Conseil,2
Mathias
Maitrejean,3
Gilles
Comte,3
Denis
Barron,3
Attilio
Di
Pietro,2
Santiago
Castanys,1 and
Francisco
Gamarro1,*
Instituto de Parasitologia y Biomedicina
"López-Neyra," Consejo Superior de Investigaciones
Científicas, Granada, Spain,1 and
Institut de Biologie et Chimie des Protéines, UPR 412 du
CNRS, Lyon,2 and Laboratoire des
Produits Naturels, UMR-CNRS 5013, Université Claude Bernard de
Lyon, Villeurbanne,3 France
Received 25 May 2000/Returned for modification 5 September
2000/Accepted 8 November 2000
 |
ABSTRACT |
In order to overcome the multidrug resistance mediated by
P-glycoprotein-like transporters in Leishmania spp., we
have studied the effects produced by derivatives of the flavanolignan
silybin and related compounds lacking the monolignol unit on (i) the
affinity of binding to a recombinant C-terminal nucleotide-binding
domain of the L. tropica P-glycoprotein-like transporter
and (ii) the sensitization to daunomycin on promastigote forms of a
multidrug-resistant L. tropica line overexpressing the
transporter. Oxidation of the flavanonol silybin to the corresponding
flavonol dehydrosilybin, the presence of the monolignol unit, and the
addition of a hydrophobic substituent such as dimethylallyl, especially
at position 8 of ring A, considerably increased the binding affinity.
The in vitro binding affinity of these compounds for the recombinant
cytosolic domain correlated with their modulation of drug resistance
phenotype. In particular, 8-(3,3-dimethylallyl)-dehydrosilybin
effectively sensitized multidrug-resistant Leishmania spp.
to daunomycin. The cytosolic domains are therefore attractive targets
for the rational design of inhibitors against P-glycoprotein-like transporters.
 |
INTRODUCTION |
Drug resistance has become a major
impediment to the treatment of diseases caused by protozoan parasites,
which threaten the life of nearly one-quarter of the human population.
Among parasitic infections, World Health Organization statistics show
that the incidence of leishmaniasis has increased 42-fold between 1985 and 1998 and has become the second leading cause of death
(18) worldwide. Chemotherapy remains the only effective
way to control infections. The conventional clinical drugs, pentavalent
antimonials in the form of Glucantime and Pentostam (reviewed in
reference 27), are not very efficient due to their
toxicity and the increased appearance of drug resistance
(14). ATP-binding cassette (ABC) transporters have been
found to be involved in Leishmania species in vitro selected
for metal resistance (reviewed in reference 30). The
multidrug resistance (MDR) phenotype due to P-glycoprotein (Pgp)-like
transporters has been extensively characterized in cancer cells
(1, 13) and protozoan parasites (41),
including Plasmodium (45) and
Leishmania (4, 5, 17) spp. Pgp is an
ATP-dependent pump that exports a wide range of drugs from the cell,
decreasing their intracellular concentration and preventing their
cytotoxic activity. Pgp belongs to the ABC superfamily of transporters.
It consists of two homologous halves, each comprising a transmembrane
domain involved in drug efflux, and a cytosolic nucleotide-binding
domain (NBD) responsible for ATP binding and hydrolysis. Pgp can be
inhibited in vitro by agents such as verapamil and cyclosporine, which
compete with drug binding to the transmembrane domains
(16). However, most of these inhibitors are also pumped substrates and therefore require high concentrations for effective inhibition. These concentrations produce undesirable side effects. In
addition, these classical modulators of drug efflux in cancer cells
only poorly sensitize the MDR phenotype in Leishmania
parasites (4, 17, 33). Thus, new classes of more specific,
nontransported inhibitors of Pgp-like transporters with lower host
toxicity need to be developed. Recently, it has been described that
NBDs can be the target for inhibitors of Pgp-like transporters
(7, 11, 33). Flavonoids, which constitute a well-known
class of natural inhibitors of different ATP-binding proteins
(28), with contradictory modulation effects on different
MDR cells (8, 15, 33, 37-39), bind to transporter NBDs.
They interact with both the ATP-binding site and a vicinal hydrophobic
region (7, 9, 33), inhibiting drug efflux and reversing
the resistance phenotype of an L. tropica MDR line
(33). Their efficient modulation of drug efflux has been
correlated with their affinity binding to the transporter cytosolic
domain (33).
Silymarin is a mixture of flavanolignans isolated from the medicinal
plant Silybum marianum, with silybin (or silybinin) (Fig. 1A) as the main component
(31). These natural compounds are well-established
hepatoprotectants and are used in Europe and Asia for the clinical
treatment of liver diseases with different aetiologies (reviewed in
references 25 and 32). Silymarin is well
tolerated as a therapeutic agent and is largely devoid of adverse
effects (25, 32). It has been recently marketed in the
United States and in Europe as a nutritional supplement. Silymarin may
directly affect cholesterol metabolism and is therefore considered as a
potential hypocholesterolemic (41). In vitro studies
indicate that silymarin and silybin may help to prevent and treat
breast, prostate, skin and ovarian cancers (32, 36, 46).
Silybin also appeared to be synergistic with doxorubicin in a
doxorubicin-resistant cell line, probably by inhibiting Pgp function
(36). Thus, silybin, either alone or in combination with
other cytotoxic drugs, is currently being tested in patients with
advanced ovarian cancer (36).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Chemical structures of silybin and derivatives. (A) The
flavanol silybin with a reduced 2,3-bond, a hydroxyl group at position
3 and the monolignol unit (rings D and E) adjacent to ring B. (B) The
flavonol DHS with oxidized 2,3-bond and derivatives substituted by
3,3-DMA or geranyl groups at either position 6 (R1) or 8 (R2) of ring
A. (C) The flavonol galangin, lacking the monolignol unit, and
derivatives substituted at position 8 (R3). (D) The flavone chrysin,
lacking both the monolignol unit and the hydroxyl group at position 3, and 8-substituted derivatives (R3).
|
|
The binding of flavonoids to Pgp (7, 33) and their
modulation of drug efflux in an L. tropica MDR line are
class dependent (33). Flavones and flavonols display
better binding affinities than the corresponding isoflavones and
flavanones. The present study has tested the ability of the flavanonol
silybin, plus its oxidized and hydrophobically substituted derivatives,
to bind to purified recombinant C-terminal NBD (NBD2) of a
Leishmania Pgp-like transporter and to sensitize the MDR
phenotype. The oxidation of silybin to its corresponding flavonol and
the prenylation of the latter, especially at position 8, dramatically
increased the binding affinity for NBD2 and the sensitization of an
L. tropica MDR line overexpressing the transporter, thereby
inhibiting growth in the presence of the daunomycin.
 |
MATERIALS AND METHODS |
Chemical compounds.
HECAMEG
[6-O-[(N-heptylcarbamoyl)methyl]-
-D-glucopyranoside]
was purchased from Calbiochem, daunomycin was obtained from Pharmacia & Upjohn (Barcelona, Spain), and imidazole (catalog reference I 0250) was
from Sigma. Commercial flavonoids were obtained from either Aldrich
(galangin) or Sigma (chrysin and silybin). 1,1-DMA-chrysin
(3), 1,1-DMA-galangin (2) and the derivatives of silybin (26) were synthesized as described.
3,3-DMA-chrysin was from the Natural Products Laboratory collections of compounds.
Synthesis of 8-(3,3-DMA)-galangin.
To a stirred solution of
1.2 g of galangin (4.4 mmol) and 1.6 g of tetraethylammonium
iodide (6.2 mmol) in 70 ml of 10% aqueous tetramethylammonium
hydroxide was added 1 ml of prenyl bromide (8.7 mmol) dropwise at room
temperature. After a 90-min reaction, the medium was acidified to pH 1 (with HCl, 1 N) and extracted with ethyl acetate. Isolation of
8-(3,3-DMA)-galangin (0.19 g, 0.6 mmol, 14%) from the ethyl acetate
extract was carried out by medium pressure liquid chromatography on a
C18 reversed-phase column using a gradient of methanol in
water as solvent. The 1H nuclear magnetic resonance
(acetone-d6, 300 MHz) variables were as follows:
12.02 (1H, s, 5-OH),
8.30 (2H, m, H-2'+6'),
7.55 (3H, m,
H-3'+4'+5'),
6.40 (1H, s, H-6),
5.30 (1H,
brt, J = 6.5 Hz, H-2),
3.59 (2H, d,
J = 6.5 Hz, H-1 ),
1.83 (3H, s, H-5 ),
and
1.67 (3H, s, H-4 ). For electron impact mass
spectrometry (EIMS) (70 eV), the m/z (rel. int.) values were
338 [M]+ (94), 323 (100), 283 (72), and 270 (42). For high-resolution EIMS,
the m/z value was 338.1155 (as calculated for
C20H18O5 = 338.1154).
Parasite culture and in vitro experiments.
The wild-type
L. tropica LRC strain was a clone obtained by agar plating
(19). An L. tropica line highly resistant to
daunomycin (DNM-R150) was maintained in the presence of 150 µM
daunomycin and used as previously described (4). This
resistant line had an MDR phenotype similar to that of tumor cells,
with cross-resistance to several drugs and an overexpressed drug efflux
Pgp-like transporter (4). Promastigote forms were grown at
28°C in RPMI 1640-modified medium (Gibco) (20) and
supplemented with 20% heat-inactivated fetal bovine serum (Gibco). The
growth sensitivity of wild-type and drug-resistant parasites to
modulators of drug efflux was ascertained as described earlier
(33, 34).
Overexpression, protein purification, and interaction of
Leishmania NBD2 with silybin and derivatives.
The
recombinant NBD2 from Leishmania Pgp-like transporter was
overexpressed in E. coli M15 (pREP4) cells and purified by
affinity chromatography (33). Fluorescence experiments
were performed at 25.0 ± 0.1°C using an SLM-Aminco 8000C
spectrofluorimeter with spectral bandwidths of 2 and 4 nm for
excitation and emission, respectively. The measurements were corrected
for wavelength dependence on the excitation light intensity by using
rhodamine B in the reference channel. All spectra were corrected for
buffer Raman effect and for dilution. The intrinsic fluorescence of
NBD2 (0.2 to 0.5 µM final concentration) was measured in 1 ml of
diluting buffer (50 mM potassium phosphate, pH 8.0; 1 M NaCl; 20%
[wt/vol] glycerol, 0.05% [wt/vol] HECAMEG; 1 mM
-mercaptoethanol; 10 mM imidazole), with increasing concentrations
of silybin or derivatives dissolved in dimethyl sulfoxide. The emission
spectrum was measured in the range of 300 to 350 nm upon excitation at
288 nm (a wavelength which minimized imidazole interference [33,
34]). Ligand binding was monitored by the quenching of emission
fluorescence produced upon addition of increasing ligand
concentrations. Corrections for the inner-filter effect and dimethyl
sulfoxide addition (up to a 2% final concentration) were determined
under the same conditions, by using a mixture of
N-acetyltryptophanamide and N-acetyltyrosinamide in the same ratio (3:7) as the tryptophan and tyrosine residues present
in NBD2. Curve fitting of ligand binding-related fluorescence quenching
was analyzed with the Grafit program (Erithacus Software) (12). This allowed the determination of the apparent
dissociation constant (Kd) and maximal quenching
of fluorescence.
 |
RESULTS |
Interaction of NBD2 with silybin and derivatives.
Incubation
of recombinant NBD2 with the naturally occurring flavanolignan silybin
(Fig. 1A) produced the concentration-dependent quenching of protein
intrinsic fluorescence illustrated in Fig. 2A. Detailed analysis of binding (Fig.
2B) gave an apparent dissociation constant (Kd)
of 9.2 ± 1.0 µM. Oxidation of the 2,3-bond of ring C in silybin
to the corresponding flavonol dehydrosilybin (DHS) (Fig. 1B), gave a
fourfold-higher binding affinity for the domain (Fig. 2B, with a
Kd of 2.3 ± 0.2 µM). A further 3.5- to
21-fold increase in binding affinity was produced by addition of
hydrophobic substituents (dimethylallyl [DMA] or geranyl) at either
position 6 or position 8 of ring A, with Kd
values in the nanomolar range (Table 1).
The effect was dependent on both the nature and the position of the
hydrophobic substituent. Thus, a 3,3-DMA group at position 6 or 8 of
ring A increased the binding affinity a further 2.5- to 3-fold more,
respectively, than a geranyl group at the same positions (Table 1). In
addition, the hydrophobic substitution at position 8 of ring A by
either prenyl or geranyl substituent gave twofold-greater affinity than
substitution at position 6 (Table 1). Thus, the 8-(3,3-DMA)-DHS
derivative gave the highest binding affinity, with a
Kd of 0.11 ± 0.02 µM. This value was
85-fold less than that obtained with unmodified silybin.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Interaction of recombinant Leishmania NBD2
with silybin and derivatives monitored by the quenching of protein
intrinsic fluorescence. (A) Spectral modification upon interaction with
silybin. The fluorescence spectrum of 0.5 µM NBD2 was recorded after
excitation at 288 nm, in the absence (continuous line) or presence of
either 4 µM (broken line) or 16 µM (dotted line) silybin; the
traces were obtained by buffer subtraction before correction for
inner-filter effect. (B) The concentration-dependent binding of silybin
and derivatives was analyzed by quenching of NBD2 intrinsic
fluorescence, determined by spectral integration from 300 to 350 nm,
and corrected for the inner-filter effect in the presence of increasing
concentrations of either silybin ( ), DHS ( ), or 8-(3,3-DMA)-DHS
( ) added as a dimethyl sulfoxide solution.
|
|
The effect of prenylation at position 8 was further studied within the
compounds galangin and chrysin (Fig.
1C and D), lacking
the monolignol
unit. When compared to DHS, the binding affinity
for NBD2 was reduced
fourfold for galangin and eightfold for chrysin
that also lacks an
hydroxyl group at position 3 of ring C (Table
2). In both cases, prenylation by 3,3-DMA
at position 8 also
markedly increased (6- to 15-fold) the binding
affinity. A double
increase (12- to 28-fold) was even obtained with the
1,1-DMA substituent.
Sensitization of promastigote forms by silybin and its
derivatives.
The resistance to daunomycin in the MDR L. tropica line is mainly due to the overexpression of a Pgp-like
transporter involved in drug efflux (4) which limits drug
accumulation. We tested whether the binding of silybin derivatives to
the cytosolic domain of the Pgp-like transporter could inhibit drug
pumping and overcome drug resistance. Potential modulators were
assessed for their ability to inhibit the growth of resistant parasites
in the presence of daunomycin, in comparison with wild-type parasites
in absence of drug. Figure 3 shows that a
72-h incubation of resistant parasites with 150 µM daunomycin in the
presence of different silybin derivatives gave differential
dose-dependent growth inhibition (GI). These studies demonstrate the
importance of silybin oxidation to DHS and the prenylation of the
latter. Consistent with the binding analysis, 8-(3,3-DMA)-DHS was the
most efficient sensitizer. It gave more than 95% GI at 10 µM and
showed only a minor toxic effect in the wild-type line. The other
hydrophobically substituted derivatives also showed considerable
sensitization of the cells (89 to 98% GI in the resistant line) at a
threefold-higher concentration (30 µM). However, this concentration
of geranyl derivatives gave significant cytotoxicity in the wild-type
parasites (31 to 62% GI). In contrast, unmodified silybin only gave
modest sensitization, even at much higher concentrations (100 to 300 µM). Silymarin also did not reverse the resistant phenotype at high
concentrations such as 250 µg/ml (data not shown). Finally, DHS
showed considerable cytotoxicity on wild-type parasite (ca. 62% GI at
20 µM). This hampered studies of its sensitization of the MDR
phenotype.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 3.
Sensitization by silybin derivatives in a
daunomycin-resistant L. tropica line. Cell growth of either
wild-type or resistant parasites was determined after incubation at
28°C for 72 h. Wild-type parasites (*) were incubated in the
presence of different concentrations of silybin derivatives. Resistant
parasites were incubated with the same concentrations of silybin
derivatives in the presence of 150 µM daunomycin. The results are
expressed as the percentage of growth inhibition observed in each cell
line compared to the absence of modulator (control cells). The data are
means with standard deviations for three experiments performed in
duplicate.
|
|
The reversal of parasite resistance to daunomycin was also tested with
prenylated derivatives of galangin and chrysin. Figure
4A shows that higher concentrations of
galangin derivatives were
required to produce ca. 80% GI in the
resistant line [20 µM 8-(1,1-DMA)-galangin
or 50 µM
8-(3,3-DMA)-galangin] compared with 8-(3,3-DMA)-DHS (5
to 10 µM),
while nonprenylated galangin produced a slight sensitization
at 75 µM. The chrysin derivatives were even less efficient (Fig.
4B): 30 µM 8-(1,1-DMA)-chrysin produced a 88% GI in the resistant
line, and
40 µM 8-(3,3-DMA)-chrysin gave 71% GI, but this concentration
was
relatively cytotoxic for the wild-type line. The nonsubstituted
chrysin
produced a small effect at 75 µM. Interestingly, in both
galangin and
chrysin derivatives, the 1,1-DMA substitution gave
better sensitivity
to daunomycin that the 3,3-DMA substitution.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 4.
Sensitization of growth caused by prenylated derivatives
lacking the monolignol unit. Wild-type (*) and resistant parasites
were incubated under the conditions of Fig. 3 with different prenylated
derivatives of galangin (A) and chrysin (B). The data are means with
standard deviations for three experiments performed in duplicate.
|
|
 |
DISCUSSION |
We show here that oxidized and prenylated derivatives of the
therapeutic agent silybin exhibit high binding affinity to the recombinant cytosolic domain of Leishmania Pgp-like
transporter and revert the MDR of an L. tropica line that
overexpresses the transporter, drawing attention to the importance of
the monolignol unit within the above compounds.
Silybin is a natural flavanolignan with many positive therapeutic
properties and few adverse effects in animals and humans. Although its
cellular target is unknown, it increased the cytotoxicity of
doxorubicin in a doxorubicin-resistant cell line (36). In order to circumvent MDR phenotype in Leishmania, we have
studied silybin binding to recombinant NBD2 of the L. tropica multidrug transporter, the effects of its oxidation to
DHS, and the effects of different hydrophobic substitutions on ring A,
previously described as critical for the increase the binding of
flavones to the cytosolic domain of Leishmania Pgp-like
transporter (33). These results, together with comparative
data for derivatives lacking the monolignol unit, provide important
structure-activity information. (i) First of all, these results
demonstrate the significance of the oxidation of 2,3-bond within the
silybin ring C to its corresponding flavonol DHS, which may reinforce
the mimicry of the adenine moiety of ATP, as previously suggested from
the higher binding affinity of the flavone apigenin compared to its
reduced analogue naringenin (7, 33). Conversely, the
reduction of the 2,3-double bond of flavones to give flavanones
resulted in a decrease of the competitive inhibition of
H+,K+-ATPase with respect to ATP
(29). (ii) They demonstrate the importance of the addition
of a prenyl or geranyl hydrophobic substituent on ring A that could
increase the interaction with the hydrophobic region vicinal to the ATP
site (33). (iii) The monolignol unit (rings D and E in
Fig. 1A and B) within flavanolignans produces significant effects
with a five- to sixfold-higher affinity for 8-(3,3-DMA)-DHS with
respect to 8-(3,3-DMA)-galangin and a fourfold higher affinity for DHS
with respect to galangin. Additional studies are needed to determine
its specific role in the interaction with the domain. (iv) These
results further demonstrate the preference for hydrophobic substitution
at position 8 over position 6 of ring A, suggesting some differences in
binding orientation of the differently substituted compounds. (v) These
results show the more efficient effect of prenylation compared to
geranylation despite a lower hydrophobicity. (vi) Finally, these
studies show the systematically more efficient effect of the 1,1-DMA
compared to 3,3-DMA.
Similar in vitro results with some of these silybin derivatives have
been obtained in parallel studies with the cytosolic domain of
mammalian Pgp (26), except that the geranyl substitution was more efficient than the prenyl one. These differential results may
indicate some differences between the cytosolic domains of Leishmania and mammalian transporters, possibly at the level
of the hydrophobic interacting region.
The same sequence in efficiency has also been obtained from the in
vitro sensitization studies in an MDR Leishmania line, so
that compounds that display higher binding affinity for the recombinant
NBD2 most efficiently sensitize the MDR phenotype. Thus, although the
reversing effects of the compounds could in some cases be partially
covered by their intrinsic cytotoxicity, as was observed for
geranyl-DHS, the importance of the monolignol unit is evident from the
higher reversion of resistance obtained with 8-(3,3-DMA)-DHS with
respect to 8-(3,3-DMA)-galangin, as well as the role of prenylation,
especially 1,1-DMA, at position 8 of ring A. Thus, 8-(3,3-DMA)-DHS is
the most active MDR-sensitizing agent ever described for
Leishmania. Work is in progress to synthesize the
8-(1,1-DMA)-DHS derivative that would probably bind with even higher
affinity to the domain and sensitize MDR at even lower concentrations.
The single exception to the correlation between binding to NBD2 and MDR
sensitization was the absence of any reversion by DHS. This appears to
be due to the high cytotoxicity caused by this compound (ca. 62% GI in
wild-type parasites at 20 µM) compared to silybin (29% at 300 µM).
Similarly, a fourfold-higher GI for DHS compared to that for silybin
has been described in a human ovarian carcinoma cell line
(36). This effect could be due to higher mimicry with ATP
after oxidation of the silybin 2,3-bond, thereby favoring additional
binding to other ATP-binding proteins. Indeed, flavonols such as DHS,
with a hydroxyl at position 3 and a 2,3-double bond in addition to the
hydroxyl at position 5 and the ketone at position 4, contain all the
requirements to bind to ATP-binding site, as previously shown not only
for L. tropica (33) and mammalian (7,
11) multidrug transporters but also for crystallized CDK2
(10) and HcK (40).
We propose that prenylation of the ring A within these compounds might
generate more specific inhibitors of Pgp-like transporters by
strengthening the interaction with its cytosolic domains, possibly with
the hydrophobic region vicinal to the ATP site. This would, on the one
hand, increase the reversal efficiency on the MDR parasites and, on the
other hand, lower the affinity for other cellular ATP-binding proteins,
as deduced from the significant decrease of the cytotoxicity on
wild-type parasites after prenylation (ca. 10% GI for 40 µM
6-prenyl-DHS compared to nearly 100% GI for DHS at the same
concentration; data not shown)
A number of observations have indicated flavonoid antagonism toward
ATP: (i) the binding of kaempferide or derivatives to recombinant NBD2
from either mammalian (7) or Leishmania
(33) multidrug transporter was partly prevented or
displaced by ATP; (ii) flavonoid inhibition of several ATP-utilizing
enzymes involves competitive interaction at the ATP-binding site
(28), as studied in detail for
H+,K+-ATPase (29) and as clearly
demonstrated by crystallization experiments with the protein kinases
CDK2 (10) and Hck (40); and (iii) the
flavonol quercetin, on the one hand, competitively inhibited the ATPase
activity of a recombinant NBD2 from the cystic fibrosis transmembrane
conductance regulator (another ABC protein) (35) and, on
the other hand, prevented Hoechst 33342 transport by mammalian Pgp,
partly by inhibiting its ATPase activity (38). We show
here that the sensitization caused by silybin derivatives in an MDR
L. tropica line correlates with their affinity of binding to
the cytosolic NBD2, which is consistent with a previous correlation between the binding affinity of other flavonoids for NBD2 and the
increase of intracellular daunomycin accumulation monitored by flow
cytometry (33). All of these results suggest that the reversion of drug resistance caused by silybin derivatives was produced
by direct interaction with the nucleotide-binding domain of the
Pgp-like transporter. However, other factors such as interaction with
membrane phospholipids, altering the lipid packing density and the
diffusion rate of the drug (6), or modulation of the multidrug transporter expression (22) may contribute to
the observed sensitization of MDR. In addition, it is possible that prenylated derivatives might mainly interact at the hydrophobic region
characterized within the NBDs or bind to the drug-binding sites within
the transmembrane domains of the Pgp-like multidrug transporter.
Quercetin has indeed been proposed to interact at the mammalian Pgp
site where the transported drugs Hoechst 33342 and colchicine bind,
which stimulated the transport of anthracyclines (38).
Additional work is therefore required to further characterize the
flavonoid-binding site(s).
In India, recent clinical studies showed that approximately 50% of
patients with leishmaniasis fail to achieve parasite clearance after a
standard dose of pentavalent antimonials (42). The in vivo
data are supported by in vitro monitoring of drug sensitivity of fresh
clinical isolates obtained at the same study site (24). The high rate of therapeutic failure to these usual drugs in cases of
leishmaniasis call for new rational approaches to develop alternative drugs. Some pharmaceutical compounds, such as azoles and rifampin (27), and other drugs considered as potential
leishmanicidal agents, such as doxorubicin (23), taxol
(21) and alkyl lysophospholipids (44), are
known substrates of Pgps or other ABC transporters and thus could
induce an MDR phenotype. The development of inhibitors which block the
MDR mechanism is a promising potential way to circumvent resistance to
drugs. Our studies also provide useful models for understanding how
similar defense mechanisms can be overcome in other protozoan parasites
such as Plasmodium, Entamoeba, and
Trichomonas spp., where ABC transporters have been
associated with drug resistance.
 |
ACKNOWLEDGMENTS |
This work was supported by the Spanish Grants PM97-0139 (F.G.),
PM98-0115 (S.C.), and CICYT-FEDER IFD97-0747-C04-03 (S.C.) and the
Convenio CSIC-CNRS between F.G. and A.D.P. (1997-2000). J.M.P.-V.
received a fellowship from the Junta de Andalucía (Spain), F.J.P.-V. received a fellowship from the Ministerio de Educación y Cultura (Spain), G.C. received fellowship from the Ligue Nationale contre le Cancer (Haute-Savoie, France), and M.M. received a fellowship from the French Ministry of National Education and Technological Research. Financial support from the Association pour la Recherche sur
le Cancer (ARC 9147) and the Ligue Nationale contre le Cancer (Rhône 1999) is also acknowledged.
We thank Pilar Navarro for the help in parasite culture. We also
acknowledge Pharmacia & Upjohn (Barcelona, Spain) for providing the
daunomycin used in this study and Brian Monk for improving the English
of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Instituto de
Parasitologia y Biomedicina "López-Neyra," Consejo Superior
de Investigaciones Cientificas, c/Ventanilla 11, 18001 Granada, Spain.
Phone: 34-958-805185. Fax: 34-958-203323. E-mail:
gamarro{at}ipb.csic.es.
 |
REFERENCES |
| 1.
|
Ambudkar, S. V.,
S. Dey,
C. A. Hrycyna,
M. Ramachandra,
I. Pastan, and M. Gottesman.
1999.
Biochemical, cellular and pharmacological aspects of the multidrug transporter.
Annu. Rev. Pharmacol. Toxicol.
39:361-398[CrossRef][Medline].
|
| 2.
|
Barron, D.,
C. El Aidi, and A. M. Mariotte.
1994.
13C nuclear magnetic resonance analysis of two prenyl flavonols from Platanus acerifolia buds.
Phytochem. Anal.
5:309-314.
|
| 3.
|
Barron, D., and A. M. Mariotte.
1994.
Syntheses of 8-C-(1,1-dimethylallyl) flavones and 3-methyl flavonols.
Nat. Prod. Lett.
4:21-28.
|
| 4.
|
Chiquero, M. J.,
J. M. Pérez-Victoria,
F. O'Valle,
J. M. Gonzalez-Ros,
R. del Moral,
J. A. Ferragut,
S. Castanys, and F. Gamarro.
1998.
Altered drug membrane permeability in a multidrug-resistant Leishmania tropica line.
Biochem. Pharmacol.
55:131-139[CrossRef][Medline].
|
| 5.
|
Chow, L. M. C.,
A. K. C. Wong,
B. Ullman, and D. F. Wirth.
1993.
Cloning and functional analysis of an extrachromosomally amplified multidrug resistance-like gene in Leishmania enrietti.
Mol. Biochem. Pharmacol.
60:195-208.
|
| 6.
|
Clarke, R.,
H. W. Van den Berg, and R. F. Murphy.
1990.
Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17 beta-estradiol.
J. Natl. Cancer Inst.
82:1702-1705[Abstract/Free Full Text].
|
| 7.
|
Conseil, G.,
H. Baubichon-Cortay,
G. Dayan,
J. M. Jault,
D. Barron, and A. Di Pietro.
1998.
Flavonoids: a new class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein.
Proc. Natl. Acad. Sci. USA
95:9831-9836[Abstract/Free Full Text].
|
| 8.
|
Critchfield, J. W.,
C. J. Welsh,
J. M. Phang, and G. C. Yeh.
1994.
Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells: activation of P-glycoprotein as a possible mechanism.
Biochem. Pharmacol.
48:1437-1445[CrossRef][Medline].
|
| 9.
|
Dayan, G.,
J. M. Jault,
H. Baubichon-Cortay,
L. G. Baggetto,
J. M. Renoir,
E. E. Baulieu,
P. Gros, and A. Di Pietro.
1997.
Binding of steroid modulators to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site.
Biochemistry
36:15208-15215[CrossRef][Medline].
|
| 10.
|
De Azevedo, W. F., Jr.,
H. J. Mueller-Dieckmann,
U. Schulze-Gahmen,
P. J. Worland,
E. Sausville, and S. H. Kim.
1996.
Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
Proc. Natl. Acad. Sci. USA
93:2735-2740[Abstract/Free Full Text].
|
| 11.
|
Di Pietro, A.,
G. Dayan,
G. Conseil,
E. Steinfels,
T. Krell,
D. Trompier,
H. Baubichon-Cortay, and J. M. Jault.
1999.
P-glycoprotein-mediated resistance to chemoterapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationship.
Braz. J. Med. Biol. Res.
32:925-939[Medline].
|
| 12.
|
Divita, G.,
R. S. Goody,
D. C. Gautheron, and A. Di Pietro.
1993.
Structural mapping of catalytic site with respect to alpha-subunit and noncatalytic site in yeast mitochondrial F1-ATPase using fluorescence resonance energy transfer.
J. Biol. Chem.
268:13178-13186[Abstract/Free Full Text].
|
| 13.
|
Endicott, J. A., and V. Ling.
1989.
The biochemistry of P-glycoprotein-mediated multidrug resistance.
Annu. Rev. Biochem.
58:137-171[CrossRef][Medline].
|
| 14.
|
Faraut-Gambarelli, F.,
R. Piarroux,
M. Deniau,
B. Giusiano,
P. Marty,
G. Michel,
B. Faugere, and H. Dumon.
1997.
In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis.
Antimicrob. Agents Chemother.
41:827-830[Abstract].
|
| 15.
|
Ferté, J.,
J. M. Kühnel,
G. Chapuis,
Y. Rolland,
G. Lewin, and M. A. Schwaller.
1999.
Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity, and structure-activity relationships.
J. Med. Chem.
42:478-489[CrossRef][Medline].
|
| 16.
|
Ford, J. M., and W. N. Hait.
1990.
Pharmacology of drugs that alter multidrug resistance in cancer.
Pharmacol. Rev.
42:155-199[Medline].
|
| 17.
|
Henderson, D. M.,
C. D. Sifri,
M. Rodgers,
D. F. Wirth,
N. Hendrickson, and B. Ullman.
1992.
Multidrug resistance in Leishmania donovani is conferred by amplification of a gene homologous to the mammalian mdr1 gene.
Mol. Cell. Biol.
12:2855-2865[Abstract/Free Full Text].
|
| 18.
|
Hirst, S. I., and L. A. Stapley.
2000.
Parasitology: the dawn of a new millennium.
Parasitol. Today
16:1-3[CrossRef][Medline].
|
| 19.
|
Iovannisci, D. M., and B. Ullman.
1983.
High efficiency plating method for Leishmania promastigotes in semi-defined or completely-defined medium.
J. Parasitol.
69:633-636[CrossRef][Medline].
|
| 20.
|
Jackson, P. R.,
J. M. Lawrie,
J. M. Stiteler,
D. W. Hawkins,
J. A. Wohlhieter, and E. D. Rowtin.
1986.
Detection and characterization of Leishmania species and strains from mammals and vectors by hybridization and restriction endonuclease digestion of kinetoplast DNA.
Vet. Parasitol.
20:195-215[CrossRef][Medline].
|
| 21.
|
Kapoor, P.,
M. Sachdeva, and R. Madhubala.
1999.
Effect of the microtubule stabilising agent taxol on leishmanial protozoan parasites in vitro.
FEMS Microbiol. Lett.
176:429-435[CrossRef][Medline].
|
| 22.
|
Kioka, N.,
N. Hosokawa,
T. Komano,
K. Hirayoshi,
K. Nagata, and K. Ueda.
1992.
Quercetin, a bioflavonoid, inhibits the increase of human multidrug resistance gene (MDR1) expression caused by arsenite.
FEBS Lett.
301:307-309[CrossRef][Medline].
|
| 23.
|
Kole, L.,
L. Das, and P. K. Das.
1999.
Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimented visceral leishmaniasis.
J. Infect. Dis.
180:811-820[CrossRef][Medline].
|
| 24.
|
Lira, R.,
S. Sundar,
A. Makharia,
R. Kenney,
A. Gam,
E. Saraiva, and D. Sacks.
1999.
Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.
J. Infect. Dis.
180:564-567[CrossRef][Medline].
|
| 25.
|
Luper, S.
1998.
A review of plants used in the treatment of liver diseases: part 1.
Altern. Med. Rev.
3:410-421[Medline].
|
| 26.
|
Maitrejean, M.,
G. Comte,
D. Barron,
K. El Kirat,
G. Conseil, and A. Di Pietro.
2000.
The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein.
Bioorg. Med. Chem. Lett.
10:157-160[CrossRef][Medline].
|
| 27.
|
Marsella, R., and R. Ruiz de Gopegui.
1998.
Leishmaniasis: a re-emerging zoonosis.
Int. J. Dermatol.
37:801-814[CrossRef][Medline].
|
| 28.
|
Middleton, E., and C. Kandaswami.
1993.
The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer, p. 619-652.
In
J. B. Harborne (ed.), The flavonoids: advances in research since 1986. Chapman Hall, London, England.
|
| 29.
|
Murakami, S.,
M. Muramatsu, and K. Tomisawak.
1999.
Inhibition of gastric H+,K+-ATPase by flavonoids: a structure-activity study.
J. Enzyme Inhib.
14:151-166[Medline].
|
| 30.
|
Ouellette, M.,
D. Légaré,
A. Haimeur,
K. Grondin,
G. Roy,
C. Brochu, and B. Papadopoulou.
1998.
ABC transporters in Leishmania and their role in drug resistance.
Drug Res. Updates
I:43-48.
|
| 31.
|
Pelter, A., and R. Hansel.
1968.
The structure of silybin (Silybum substance E6), the first flavanolignan.
Tetrahedron Lett.
1968:2911-2916[CrossRef].
|
| 32.
|
Pepping, J.
1999.
Milk tistle: Silibum marianum.
Am. J. Health-Syst. Pharm.
56:1195-1197[Free Full Text].
|
| 33.
|
Pérez-Victoria, J. M.,
M. J. Chiquero,
G. Conseil,
G. Dayan,
A. Di Pietro,
D. Barron,
S. Castanys, and F. Gamarro.
1999.
Correlation between the affinity of flavonoids binding to cytosolic site of Leishmania tropica multidrug transporter and their efficiency to revert parasite resistance to daunomycin.
Biochemistry
38:1736-1743[CrossRef][Medline].
|
| 34.
|
Pérez-Victoria, J. M.,
B. M. Tincusi,
I. A. Jiménez,
I. L. Bazzocchi,
M. P. Gupta,
S. Castanys,
F. Gamarro, and A. G. Ravelo.
1999.
New natural sesquiterpenes as modulators of daunomicyn resistance in a multidrug-resistant Leishmania tropica line.
J. Med. Chem.
42:4388-4393[CrossRef][Medline].
|
| 35.
|
Randack, C.,
E. A. Auerswald,
Y. Assfalg-Machleidt,
W. W. Reenstra, and W. Machleidt.
1999.
Inhibition of ATPase, GTPase and adenylate kinase activities of the second nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator by genistein.
Biochem. J.
340:227-235.
|
| 36.
|
Scambia, G.,
R. De Vincenzo,
F. O. Ranelletti,
P. B. Panici,
G. Ferrandina,
G. D'Agostino,
A. Fattorossi,
E. Bombardelli, and S. Mancuso.
1996.
Antiproliferative effect of silybin on gynaecological malignacies: synergism with cisplatin and doxorubicin.
Eur. J. Cancer
32:877-882[CrossRef].
|
| 37.
|
Scambia, G.,
F. O. Ranelletti,
P. Benedetti Panici,
R. De Vincenzo,
G. Bonanno,
G. Ferrandina,
M. Piantelli,
S. Bussa,
C. Rumi,
M. Cianfriglia, and S. Mancuso.
1994.
Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast cancer cell line: P-glycoprotein as a possible target.
Cancer Chemother. Pharmacol.
34:459-464[Medline].
|
| 38.
|
Shapiro, A. B., and V. Ling.
1997.
Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein.
Biochem. Pharmacol.
53:587-596[CrossRef][Medline].
|
| 39.
|
Shapiro, A. B., and V. Ling.
1997.
Positivily cooperative sites for drug transport by P-glycoprotein with disting drug specificities.
Eur. J. Biochem.
250:130-137[Medline].
|
| 40.
|
Sicheri, F.,
I. Moarefi, and J. Kuriyan.
1997.
Crystal structure of the Src family tyrosine kinase Hck.
Nature
385:602-609[CrossRef][Medline].
|
| 41.
|
Skottova, N., and V. and Krecman.
1998.
Silymarin as a potential hypocholesteroalemic drug.
Physiol. Res.
47:1-7[Medline].
|
| 42.
|
Sundar, S.,
V. P. Singh, and H. W. Murray.
1997.
Current epidemic of visceral leishmaniasis in India.
Acta Parasitol. Turc.
21:128.
|
| 43.
|
Ullman, B.
1995.
Multidrug resistance and P-glycoproteines in parasitic protozoa.
J. Bioenerg. Biomembr.
27:77-84[CrossRef][Medline].
|
| 44.
|
Urbina, J. A.
1997.
Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites.
Parasitology
114:91-99.
|
| 45.
|
Wilson, C. M.,
A. E. Serrano,
A. Wasley,
M. P. Bogenschutz,
A. H. Shankar, and D. F. Wirth.
1989.
Amplification of a gene related to the mammalian mdr genes in drug resistance Plasmodium falciparum.
Science
244:1184-1186[Abstract/Free Full Text].
|
| 46.
|
Zi, X., and R. Agarwal.
1999.
Silybinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention.
Proc. Natl. Acad. Sci. USA
96:7490-7495[Abstract/Free Full Text].
|
Antimicrobial Agents and Chemotherapy, February 2001, p. 439-446, Vol. 45, No. 2
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.2.439-446.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Perez-Victoria, J. M., Cortes-Selva, F., Parodi-Talice, A., Bavchvarov, B. I., Perez-Victoria, F. J., Munoz-Martinez, F., Maitrejean, M., Costi, M. P., Barron, D., Di Pietro, A., Castanys, S., Gamarro, F.
(2006). Combination of Suboptimal Doses of Inhibitors Targeting Different Domains of LtrMDR1 Efficiently Overcomes Resistance of Leishmania spp. to Miltefosine by Inhibiting Drug Efflux.. Antimicrob. Agents Chemother.
50: 3102-3110
[Abstract]
[Full Text]
-
Perez-Victoria, J. M., Perez-Victoria, F. J., Parodi-Talice, A., Jimenez, I. A., Ravelo, A. G., Castanys, S., Gamarro, F.
(2001). Alkyl-Lysophospholipid Resistance in Multidrug-Resistant Leishmania tropica and Chemosensitization by a Novel P-Glycoprotein-Like Transporter Modulator. Antimicrob. Agents Chemother.
45: 2468-2474
[Abstract]
[Full Text]